^
    Back
    Association details:
    Biomarker:TNFRSF8 expression
    Cancer:Cutaneous T-cell Lymphoma
    Drug:Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Blood Adv
    Title:

    Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data

    Published date:
    12/14/2021
    Excerpt:
    Final data demonstrated improved responses per independent review facility with brentuximab vedotin vs We report final data from ALCANZA (median follow-up, 45.9 months). Adults with previously treated CD30-expressing MF/C-ALCL were randomly assigned to brentuximab vedotin...physician's choice: ORR4; 54.7% vs 12.5% (P < .001); complete response, 17.2% vs 1.6% (P = .002). Median PFS with brentuximab vedotin vs physician's choice was 16.7 months vs 3.5 months (P < .001). Median time to the next treatment was significantly longer with brentuximab vedotin than with physician's choice (14.2 vs 5.6 months; hazard ratio, 0.27; 95% confidence interval, 0.17-0.42; P < .001)...These final analyses confirm improved, clinically meaningful, durable responses and longer PFS with brentuximab vedotin vs physician's choice in CD30-expressing MF or C-ALCL.
    DOI:
    10.1182/bloodadvances.2021004710
    Trial ID:
    ALCANZA
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Peripheral T-cell Lymphoma)
    Excerpt:
    ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of adult patients with:...Previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

    Excerpt:
    ......
    Trial ID:
    NCI-2022-03831
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

    Excerpt:
    ...Patients with either Hodgkin lymphoma or T-cell lymphoma must have expression of CD30 in ≥10% of lymphoma cells....
    Trial ID:
    EpiBrentlen
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

    Excerpt:
    ...Rate of objective global response defined as proportion of patients achieving complete response (CR)/partial response (PR) that lasts at least 4 months`Complete response defined as proportion of patients achieving CR according to Olsen criteria`Progression free survival (PFS) according to Olsen criteria`Change in pruritus visual analogue scale (VAS)`CD30 expression assessed by lymph node and/or skin biopsies via immunochemistry...
    Trial ID:
    NCT03373305
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Imaging study with brentuximab in patients with lymphoma Beeldvormend onderzoek met brentuximab bij patiënten met lymfeklierkanker

    Excerpt:
    ...• A feasible and optimized 89Zr-brentuximab imaging protocol in patients with CD30+ lymphomas• Safety profile, pharmacokinetics (PK), and pharmacodynamics (PD) of the tracer 89Zr-brentuximab• The relationship between 89Zr-brentuximab biodistribution (tumor uptake) and CD30 protein expression (IHC), soluble CD30 measurements (ELISA), as well as CD30 RNA expression (nanostring). ...
    Trial ID:
    2021-005950-27
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

    Excerpt:
    ......
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

    Excerpt:
    ...Response rate is percentage of participants with skin lesions that express CD30+ receiving SGN-35 in primary cutaneous ALCL, MF, and extensive lymphomatoid papulosis whose best response during the observation period is a Partial Response (PR), regression of measurable disease, or Complete Response (CR), complete disappearance of all clinical evidence of disease, (i.e. at least moderate improvement). ...
    Trial ID:
    NCT01352520
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Exp Hematol Oncol
    Title:

    Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine

    Published date:
    05/13/2021
    Excerpt:
    We report the successful treatment of a 68-year-old man who suffered PCGD-TCL with a combination of Brentuximab Vedotin and Gemcitabine after the failure of two lines of previous chemotherapy. CD30 expression was only partial.
    Secondary therapy:
    gemcitabine
    DOI:
    10.1186/s40164-021-00225-2